Troglitazone for Type II Diabetes.
There is no conclusive evidence that troglitazone offers any clear clinical advantage over existing drug therapies. Troglitazone is only the first of a number of new antidiabetic agents. The costs of these drugs is likely to be substantially higher than existing drugs. Many other new developments in diabetes treatment, for example, nasal sprays and insulin patches, are also emerging in this field. Results of ongoing trials, and the possible identification of benefits to lowering glucose levels in pre-diabetic individuals, may open up new indications for the use of troglitazone to an even larger segment of the Canadian population.
D002170:Canada; D002839:Chromans / Q000191:economics / Q000627:therapeutic use*; D017281:Cost of Illness; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use; D013673:Technology Assessment, Biomedical; D013844:Thiazoles / Q000191:economics / Q000627:therapeutic use*
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles